COMUNICADO: La Comisión Europea aprueba IMBRUVICA(TM) para dos cánceres sanguíneos (y 3)

1) Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK
inhibitors in clinical development. J Hematol Oncol 2013;6:59.
2) European Medicines Agency. Committee for Medicinal Products for Human Use:
Summary of opinion. Disponible en:
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003791/WC500170191.pdf
!
_http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/07/news_
detail_002142.jsp&mid=WC0b01ac058004d5c1. Consultado en octubre de 2014.
3) American Cancer Society. What is chronic lymphocytic leukemia? Disponible en:
http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-what-is-cll
. Consultado en julio de 2014.
4) Schnaiter A, Stilgenbauer S. 17p Deletion in chronic lymphocytic leukemia:
risk stratification and therapeutic approach. Hematol Oncol Clin N Am 2013;27:289-301.
5) McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and
management of mantle cell lymphoma. Br J Haematol. 2012;159:405-26.
6) Williams ME, Dreyling M, Winter J, Muneer S, Leonard JP. Management of mantle
cell lymphoma: key challenges and next steps. Clin Lymphoma Myeloma Leuk.
2010;10:336-46.
7) Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in
previously treated chronic lymphoid leukemia. N Engl J Med. 2014 May 31 [epub ahead of
print].
8) IMBRUVICA(TM) (ibrutinib) Summary of Product Characteristics. Octubre de
2014.
9) Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or
refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
10) European Medicines Agency. How is the medicine expected to work?
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&mid=WC0b01ac058001d12b
. Acceso septiembre de 2014
11) Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines
Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl.6):vi50-4.
12) Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies
in Europe by morphologic subtype: results of the HAEMACARE project. Blood
2010;116:3724-34.
13) Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in
chronic lymphocytic leukemia. Cancer Control 2012;19:18-25.Stilgenbauer S, Zenz T.
Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia. Hematology
2010;481-8.
14) Stilgenbauer S, Zenz T. Understanding and Managing Ultra High-Risk Chronic
Lymphocytic Leukemia. Hematology 2010;481-8.
15) Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline.
Blood. 2013;112(23).
16) Santos FPS, O'Brien S. Small Lymphocytic Lymphoma and Chronic Lymphocytic
Leukemia Are They the Same Disease? The Cancer Journal. 2012;8(5):396-403.
17) Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and
other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011;21:293-8.
18) Leukemia and Lymphoma Society. Mantle cell lymphoma facts. Disponible en:
http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/mantlecelllymphoma.pdf
Last accessed May 14, 201

October 2014

Photo:
http://photos.prnewswire.com/prnh/20140324/NY88746LOGO

Video:
http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll

CONTACTO: Consultas de medios: Satu Kaarina Glawe, Móvil:+49(172)294-6264, E-mail: sglawe@its.jnj.com / Relaciones para inversores:Stan Panasewicz, Tel: +1-732-524-2524 - Louise Mehrotra, Tel:+1-732-524-6491